These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 20048722

  • 41. In search of second-generation HIV integrase inhibitors: targeting integration beyond strand transfer.
    Voet AR, Maeyer MD, Debyser Z, Christ F.
    Future Med Chem; 2009 Oct; 1(7):1259-74. PubMed ID: 21426102
    [Abstract] [Full Text] [Related]

  • 42. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
    Burger DM.
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges.
    Lenz JC, Rockstroh JK.
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1139-50. PubMed ID: 20712521
    [Abstract] [Full Text] [Related]

  • 45. HIV integrase as a target for antiretroviral therapy.
    Hazuda DJ.
    Curr Opin HIV AIDS; 2012 Sep; 7(5):383-9. PubMed ID: 22871634
    [Abstract] [Full Text] [Related]

  • 46. HIV-1 integrase inhibitors: 2007-2008 update.
    Ramkumar K, Serrao E, Odde S, Neamati N.
    Med Res Rev; 2010 Nov; 30(6):890-954. PubMed ID: 20135632
    [Abstract] [Full Text] [Related]

  • 47. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.
    Bar-Magen T, Donahue DA, McDonough EI, Kuhl BD, Faltenbacher VH, Xu H, Michaud V, Sloan RD, Wainberg MA.
    AIDS; 2010 Sep 10; 24(14):2171-9. PubMed ID: 20647908
    [Abstract] [Full Text] [Related]

  • 48. HIV-1 integrase inhibitors: a review of their chemical development.
    Ingale KB, Bhatia MS.
    Antivir Chem Chemother; 2011 Nov 17; 22(3):95-105. PubMed ID: 22095518
    [Abstract] [Full Text] [Related]

  • 49. Recent Advances in Antiretroviral Agents: Potent Integrase Inhibitors.
    Psichogiou M, Poulakou G, Basoulis D, Paraskevis D, Markogiannakis A, Daikos GL.
    Curr Pharm Des; 2017 Nov 17; 23(18):2552-2567. PubMed ID: 28356041
    [Abstract] [Full Text] [Related]

  • 50. CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on.
    Westby M, van der Ryst E.
    Antivir Chem Chemother; 2010 Apr 14; 20(5):179-92. PubMed ID: 20413825
    [Abstract] [Full Text] [Related]

  • 51. Investigational agents for salvage.
    Pozniak AL.
    Curr Opin HIV AIDS; 2009 Nov 14; 4(6):524-30. PubMed ID: 20048721
    [Abstract] [Full Text] [Related]

  • 52. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments.
    Menéndez-Arias L.
    Antiviral Res; 2013 Apr 14; 98(1):93-120. PubMed ID: 23403210
    [Abstract] [Full Text] [Related]

  • 53. The clinical pharmacology of antiretrovirals in development.
    Winston A, Mallon PW, Boffito M.
    Expert Opin Drug Metab Toxicol; 2006 Jun 14; 2(3):447-58. PubMed ID: 16863445
    [Abstract] [Full Text] [Related]

  • 54. Dolutegravir for the treatment of HIV.
    Katlama C, Murphy R.
    Expert Opin Investig Drugs; 2012 Apr 14; 21(4):523-30. PubMed ID: 22380682
    [Abstract] [Full Text] [Related]

  • 55. Recent updates for designing CCR5 antagonists as anti-retroviral agents.
    Shah HR, Savjani JK.
    Eur J Med Chem; 2018 Mar 10; 147():115-129. PubMed ID: 29425816
    [Abstract] [Full Text] [Related]

  • 56. Novel targets for anti-retroviral therapy.
    Bhattacharya S, Osman H.
    J Infect; 2009 Dec 10; 59(6):377-86. PubMed ID: 19815027
    [Abstract] [Full Text] [Related]

  • 57. [Integrase inhibitors and CCR5 receptor antagonists].
    Tsukada K.
    Nihon Rinsho; 2012 Apr 10; 70(4):596-600. PubMed ID: 22568139
    [Abstract] [Full Text] [Related]

  • 58. Emerging drug targets for antiretroviral therapy.
    Reeves JD, Piefer AJ.
    Drugs; 2005 Apr 10; 65(13):1747-66. PubMed ID: 16114975
    [Abstract] [Full Text] [Related]

  • 59. Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents.
    Bonnenfant S, Thomas CM, Vita C, Subra F, Deprez E, Zouhiri F, Desmaële D, D'Angelo J, Mouscadet JF, Leh H.
    J Virol; 2004 Jun 10; 78(11):5728-36. PubMed ID: 15140970
    [Abstract] [Full Text] [Related]

  • 60. Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.
    Dickinson L, Khoo S, Back D.
    Antiviral Res; 2010 Jan 10; 85(1):176-89. PubMed ID: 19665485
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.